HCmed Innovations Co., Ltd., a contract development and manufacturing organization (CDMO), appointed Gunilla Petersson, Ph.D. chief scientific officer (CSO). In her role as CSO, Petersson will contribute to the company’s strategic business development, while providing professional advice with regards to combination product development.   

Former science and innovation director of inhaled drug delivery at AstraZeneca, Petersson joins HCmed with more than 29 years of experience in the pharmaceutical industry. In recent years, Petersson dedicated herself to novel technology scouting, due diligence activities, and scientific marketing.

During her extended professional career, Petersson has accumulated a vast number of connections with global pharmaceutical companies and renowned experts in the field.

“We are thrilled to have Gunilla joining the HCmed team,” said Jason Cheng, chairman of HCmed. “Her extensive experience, proven track record of success with inhaled combination products, and understanding of international business operations make her the perfect candidate to lead our team. We believe that she will help HCmed explore new business opportunities and bring beneficial advantages to our company and pharmaceutical partners.”